Rich Paul told his own clients that $200 million isn't enough money. On this episode, Sam Acho, Zach Miller, Jeff Locke, and Riccardo Stewart kick off a new series, The 1Hundred Year Family, to find out why he's right. They break down exactly where a $200 million contract actually goes: the taxes nobody explains at the rookie symposium, the 40% estate tax waiting on the back end, and the lifestyle creep that quietly sinks more careers than any bad investment. This is part one of a series on what it really takes to build wealth that outlasts your own career — and your kids', and theirs. Chapters [00:00] Introduction: Riccardo opens the new "1Hundred Year Family" series and the Pac-Man story that sparked it. [00:01] Why some things are built to last and most things aren't. [00:02] Third-generation wealth loss the real reasons families lose it all. [00:03] Rich Paul's "$200 million isn't enough" comment [00:03] Sam Acho — "True wealth is what you don't see." [00:05] Zach Miller: the income tax and 40% estate tax math on a $200M contract. [00:07] Riccardo presses on double taxation between income and estate tax. [00:08] Jeff Locke: the 4-5% retirement rule and why it doesn't work for athletes. [00:10] Lifestyle creep" why it's one of the hardest habits to reverse. [00:12] Consumerism named as the real enemy of the 1Hundred Year Family Connect with us • Call or text: 602-989-5022 • Website: https://www.athletefamilyoffice.com/ • LinkedIn: https://www.linkedin.com/company/awmcapital/ • Instagram: https://www.instagram.com/awmcapital/ • Facebook: https://www.facebook.com/awmcapital/ • X: https://twitter.com/awmcapital

In this episode, we explore the evolving landscape of incentive travel with Lisa Grimaldi, editor at Northstar Meetings Group, and returning guest Ashley Martinez. Together, they unpack the impact of global uncertainty on rewards travel, sharing new research, trends, and firsthand experiences from both group and individual perspectives. From shifting risk management strategies to increased demand for travel insurance and the growing emphasis on flexibility, this conversation offers practical insights for planners and travelers alike. Tune in for expert commentary and actionable tips on navigating travel challenges while continuing to create memorable, rewarding journeys. Chapters (00:00) Understanding Incentive Travel and Current Research (02:00) Rising Global Uncertainty and Risk Concerns (05:00) Industry Response and Focus on Risk Management (07:00) Increased Demand for Travel Insurance and Protection (09:00) Changing Program Design and Regionalization (12:00) Budget Adjustments and Shifting Participant Preferences (19:00) Communication, Flexibility, and Future Outlook Connect with Switchfly Website: https://www.switchfly.com/ LinkedIn: https://www.linkedin.com/company/switchfly/ X: https://twitter.com/switchfly YouTube: https://www.youtube.com/@SwitchflyOfficial

In Part 2 of our three-part series, Roger Ferguson Jr. gives his unfiltered read on the Fed's credibility under new Chair Kevin Warsh, compares today's AI investment boom to the dot-com bubble he watched unfold as Fed Vice Chairman, and shares what actually worries him about the future of capitalism. Connect with Us: Call or text us: 626-862-0355 Website: https://www.athletefamilyoffice.com/ YouTube: https://www.youtube.com/channel/UCc1NxpK21N1vKWEExC45YEA LinkedIn: https://www.linkedin.com/company/awmcapital/ Instagram: https://www.instagram.com/awmcapital/ X: https://twitter.com/awmcapital Facebook: https://www.facebook.com/awmcapital/ Chapters [00:00] The state of the Fed under new Chair Kevin Warsh [01:02] The Fed's five-year miss [03:13] How much patience the market will give the new chair [04:46] AI vs. the dot-com bubble [08:17] Where systemic risk actually sits this time [09:17] The Fed's blind spot [10:32] What Ferguson is optimistic about [10:59] What keeps him up at night

In this episode, we break down the full life cycle of a self-storage investment, focusing on the crucial question every investor asks: how do you actually make money? We discuss how exit strategies are planned, what drives the timing of a sale, and why relationships and trust can make or break a deal. With real-world anecdotes and honest insights, Paul unpacks the mechanics behind finding buyers, managing the closing process, and ultimately distributing returns to investors. Tune in to discover what sets successful storage investments apart and gain a deeper understanding of the core principles that drive lasting results. Ready to talk about your investment strategy? Reach out at https://www.aaastorageinvestments.com/contact New episodes every two weeks. Subscribe on Apple Podcasts, Spotify, or wherever you listen to podcasts, and send this to an investor in your network who needs to hear it. Chapters (00:00) The Importance of the Exit Decision (05:27) Finding and Selecting Buyers (09:00) Closing Process and Due Diligence (12:39) Investor Distributions and the Waterfall (18:46) Tax Considerations and K-1 Reporting (24:28) The Value of Exit Velocity (27:50) Fund Structure and Return Blending Follow and Connect with Us • LinkedIn: https://www.linkedin.com/company/aaa-storage-investments/ • Instagram: https://www.instagram.com/aaastorageinvestments/ • X: https://x.com/investments_aaa • Facebook: https://www.facebook.com/people/AAA-Storage-Investments-LLC/61575027573292/ Download our free guides to take your investing to the next level: 10 Due Diligence Questions to Vet Any Real Estate Sponsor: https://www.aaastorageinvestments.com/info/10-due-diligence-questions-to-vet-any-real-estate-sponsor First-Time Real Estate Syndication Investor Checklist: https://www.aaastorageinvestments.com/info/first-time-real-estate-syndication-investor-checklist

In this episode of "In the Interim...", Dr. Scott Berry dissects prevailing concepts of “clinically meaningful difference” in clinical trials focusing on progressive diseases. Through detailed examples from pancreatic cancer (Ben Sasse, Revolution Medicines), emphysema (Elevair), Alzheimer’s disease (lecanemab), and IVF, Scott challenges the adequacy of the population-mean of a continuous outcome in reflecting true patient benefit. The episode discusses inconsistent usage and interpretation of acronyms such as MCID, CSD, and Target Product Profile (TPP). Dr. Berry advises trialists to resist interpreting the mean difference using patient-level minimal effects, and adopt responder analyses and cumulative probability approaches to enhance patient-level relevance. Guidance is offered for analyzing the effect of time-saved instead of a mean differences in a clinical endpoint at a single time for progressive diseases – measuring “sweet time.” Key Highlights Focus on added time not the change from baseline as the most meaningful outcome for a progressive disease. In-depth evaluation of MCID, CSD, TPP, and risk of misinterpretation. Critique of trying to interpret mean-based endpoints for clinical meaningfulness such as six-minute walk distance and CDR sum of boxes. FDA advisory panel guidance on MCID for IVF live birth endpoints and dichotomous versus continuous endpoints. Advocacy for responder analyses and cumulative probability of achieving thresholds in reporting the clinical effect of a treatment. For more, visit us at https://www.berryconsultants.com/